Chiron To Sell Betaseron Assets to Schering
Schering AG (Berlin, Germany, www.schering.de) has provided Chiron Corporation (Emeryville, CA, www.chiron.com) with formal notice of its intention to purchase or lease all assets used by Chiron in the manufacture for Schering of “Betaseron” interferon beta-1b products, including all contractual rights at their fair market or lease value.
Schering is exercising its option under a change-in-control clause in a collaboration agreement with Chiron. The collaboration agreement between Schering and Chiron is expected to expire in October 2008. The purchase–lease option is subject to the closing of the pending acquisition of Chiron by
Novartis International AG
(Basel, Switzerland, www.novartis.com).
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.